TY - JOUR
T1 - Models for acute on chronic liver failure development and mortality in a veterans affairs cohort
AU - Xiao, Karen Y.
AU - Hubbard, Rebecca A.
AU - Kaplan, David E.
AU - Taddei, Tamar H.
AU - Goldberg, David S.
AU - Mahmud, Nadim
N1 - Funding Information:
This work was supported by resources and facilities available through the Philadelphia Veterans Affairs Healthcare System and central data repositories maintained by the Veterans Affairs Information Resource Center. The views expressed herein do not reflect position or policy of the Department of Veterans Affairs or the United States government.
Funding Information:
Nadim Mahmud is supported by a National Institutes of Health T32 Grant (2-T32-DK007740-21A1). Acknowledgements
Funding Information:
Karen Xiao, David Kaplan, Tamar Taddei, and Nadim Mahmud declare that they have no conflict of interest. Rebecca Hubbard has received research grants from Humana and Pfizer. David Goldberg has received research grants from Merck, AbbVie, and Gilead.
Publisher Copyright:
© 2020, Asian Pacific Association for the Study of the Liver.
PY - 2020/7/1
Y1 - 2020/7/1
N2 - Background and purpose: The diagnosis of acute on chronic liver failure (ACLF) carries a high short-term mortality, making early identification of at-risk patients crucial. To date, there are no models that predict which patients with compensated cirrhosis will develop ACLF, and limited models exist to predict ACLF mortality. We sought to create novel risk prediction models using a large North American cohort. Methods: We performed a retrospective study of 75,922 patients with compensated cirrhosis from the Veterans Outcomes and Costs Associated with Liver Disease (VOCAL) dataset. Using 70% derivation/30% validation sets, we identified ACLF patients using the Asian Pacific Association of Liver (APASL) definition. Multivariable logistic regression was used to derive prediction models (called VOCAL-Penn) for developing ACLF at 3, 6, and 12 months. We then created prediction models for ACLF mortality at 28 and 90 days. Results: The VOCAL-Penn models for ACLF development had very good discrimination [concordance (C) statistics of 0.93, 0.92, and 0.89 at 3, 6, and 12 months, respectively] and calibration. The mortality models also had good discrimination at 28 and 90 days (C statistics 0.89 and 0.88, respectively), outperforming the Model for End-stage Liver Disease (MELD), MELD-sodium, and the APASL ACLF Research Consortium ACLF scores. Conclusion: We have developed novel tools for predicting development of ACLF in compensated cirrhosis patients, as well as for ACLF mortality. These tools may be used to proactively guide patient follow-up, prognostication, escalation of care, and transplant evaluation. Graphic abstract: Receiver operating characteristic (ROC) curves for predicting development of APASL ACLF at 3 months (a), 6 months (b), and 1 year (c) [Figure not available: see fulltext.]
AB - Background and purpose: The diagnosis of acute on chronic liver failure (ACLF) carries a high short-term mortality, making early identification of at-risk patients crucial. To date, there are no models that predict which patients with compensated cirrhosis will develop ACLF, and limited models exist to predict ACLF mortality. We sought to create novel risk prediction models using a large North American cohort. Methods: We performed a retrospective study of 75,922 patients with compensated cirrhosis from the Veterans Outcomes and Costs Associated with Liver Disease (VOCAL) dataset. Using 70% derivation/30% validation sets, we identified ACLF patients using the Asian Pacific Association of Liver (APASL) definition. Multivariable logistic regression was used to derive prediction models (called VOCAL-Penn) for developing ACLF at 3, 6, and 12 months. We then created prediction models for ACLF mortality at 28 and 90 days. Results: The VOCAL-Penn models for ACLF development had very good discrimination [concordance (C) statistics of 0.93, 0.92, and 0.89 at 3, 6, and 12 months, respectively] and calibration. The mortality models also had good discrimination at 28 and 90 days (C statistics 0.89 and 0.88, respectively), outperforming the Model for End-stage Liver Disease (MELD), MELD-sodium, and the APASL ACLF Research Consortium ACLF scores. Conclusion: We have developed novel tools for predicting development of ACLF in compensated cirrhosis patients, as well as for ACLF mortality. These tools may be used to proactively guide patient follow-up, prognostication, escalation of care, and transplant evaluation. Graphic abstract: Receiver operating characteristic (ROC) curves for predicting development of APASL ACLF at 3 months (a), 6 months (b), and 1 year (c) [Figure not available: see fulltext.]
KW - AARC-ACLF
KW - Acute on chronic liver failure
KW - Asia pacific association of the study of the liver
KW - Cirrhosis
KW - Liver transplant
KW - Mortality model
KW - Outcomes model
KW - Prediction model
KW - Veterans health
KW - Veterans outcomes and costs associated with liver disease
UR - http://www.scopus.com/inward/record.url?scp=85086269176&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85086269176&partnerID=8YFLogxK
U2 - 10.1007/s12072-020-10060-y
DO - 10.1007/s12072-020-10060-y
M3 - Article
C2 - 32519219
AN - SCOPUS:85086269176
VL - 14
SP - 587
EP - 596
JO - Hepatology International
JF - Hepatology International
SN - 1936-0533
IS - 4
ER -